Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
about
Calcium channel blockers for primary Raynaud's phenomenonCalcium channel blockers for primary Raynaud's phenomenonOral vasodilators for primary Raynaud's phenomenonCalcium channel blockers for primary Raynaud's PhenomenonNifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1Cold hands--strained heart? Advances in the management of Raynaud's phenomenon and pulmonary hypertensionRaynaud's Phenomenon: A Brief Review of the Underlying MechanismsSystemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations.Recent achievements in the management of Raynaud's phenomenon.Advances in the treatment of Raynaud's phenomenon.Auricular electroacupuncture reduces frequency and severity of Raynaud attacks.Raynaud's phenomenon (secondary).Novel therapy in the treatment of scleroderma.Combination therapies for systemic sclerosis.Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.Development of agents for the treatment of systemic sclerosis.Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers.Current treatment options in systemic Sclerosis (Scleroderma).The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertensionVascular involvement in systemic sclerosis (scleroderma).Old medications and new targeted therapies in systemic sclerosis.Renin-angiotensin system mediators and Raynaud's phenomenon.Therapeutic options for digital ulcers in patients with systemic sclerosis.Hypertension in rheumatoid arthritis.The challenge of scleroderma ulcers.The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.The pathogenesis, diagnosis and treatment of Raynaud phenomenon.Scleroderma therapy: clinical overview of current trends and future perspective.Systemic sclerosis--challenges for clinical practice.Treatment of Raynaud phenomenon in systemic sclerosis.Infrared-monitored cold response in the assessment of Raynaud's phenomenon.Optimal management of digital ulcers in systemic sclerosisConsensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis.Functional autoantibodies in systemic sclerosis.Current and future direction in the management of scleroderma.Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.Digital ischemia in scleroderma spectrum of diseases.Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.Raynaud's phenomenon and vitamin D.
P2860
Q24186106-15A7892A-B4A1-472C-B794-9D72CB277939Q24200938-3FC2502B-2E3B-4278-ACEF-E70721945132Q24202210-10E9B387-AB38-4A37-B587-939A7A4FB452Q24242837-3CDD3C9E-732F-495E-85D5-8E4746B0C92CQ24805363-ACECFD09-5020-4218-81FB-8469D7024134Q24816970-564CFE26-7EA8-4BB4-9F29-7FB65E80DEA7Q28067805-479C3671-EB54-4CFA-9CE6-9D487B796C24Q31125829-5E686237-E0D4-4EB8-BA78-4689AC1941D0Q33797622-A5924A39-8F69-427A-A36C-37A5F8AFBF66Q33813778-6A602494-18DC-4EA0-8737-0106A6D7F465Q33822485-E50A238F-861D-4A3E-A700-4EF09F560F7CQ34011187-F97E1AEB-93CA-4EF6-AF79-80777C9A6ED0Q34104580-F8CDB13E-FAE8-4AE4-8F3F-B7BD302125EEQ34309698-A28D9982-86BD-4E45-ACA0-047DCCA3772BQ34368381-138BCADD-18F0-4D1A-A025-880CFFE7A445Q34481552-FD750049-2548-419B-827E-F7615F8FB77EQ34535555-B2214296-5DBC-412C-84AB-DCFF34D9FAEEQ34567929-002967A3-D918-4A9C-8369-D0E0EB5802EFQ35553721-1F8CEBFF-D2C8-4CA5-9400-E56322AC38A9Q35557424-EDCDC7F3-7113-4E52-8C3B-E929BC807C57Q36154430-EFB20A59-1785-45E3-945F-5CDA5988927EQ36604571-45C0DEB2-7592-41D3-A74C-A89CAA8141F4Q36835012-C903DC5B-BD70-419F-863E-4D5D77A17D5AQ37158219-21F3F702-5EE9-47A5-B146-D39800500C96Q37500626-6BC20779-8A7B-4A1E-B98B-9288D7CF474BQ37926767-64B7DD4B-B88B-4C4A-BECC-CACF3867FA4CQ38025285-1A0DFE83-DF27-438B-BE55-2DC40F0518C4Q38046467-5AABCF71-D884-4A15-A1C5-01E524526BC2Q38059459-171983CA-AA12-4190-A1C9-8AA16769A9F0Q38076483-72E025D3-F8F8-4422-A3FA-527417E4CE5DQ38455289-EC05975E-431E-4F75-B658-3BD625CFDAE0Q38537531-BF72DAE4-2B23-4012-BA15-07F1886262EAQ38538817-5DE33840-D4E6-4943-AFEC-066DCA79F902Q38570322-C24DF554-CCF0-4420-875F-74491EE1E3C7Q38823948-56E948C6-1107-403A-BCA1-4404F6F03216Q39576780-34DC90CC-2269-4AEC-BA4D-B35528C0BB04Q39632069-97357F9B-E0E8-4150-BFAF-CF3A7D177B54Q39951981-9103E73E-6F3D-4016-8DCD-8A72DE7F2815Q43740421-ED0CD809-A2F6-4F05-AC52-E3604287A7DDQ45342518-D4F7790A-B02E-4B3A-A809-DD053D8DE27D
P2860
Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Losartan therapy for Raynaud's ...... allel-group, controlled trial.
@ast
Losartan therapy for Raynaud's ...... allel-group, controlled trial.
@en
type
label
Losartan therapy for Raynaud's ...... allel-group, controlled trial.
@ast
Losartan therapy for Raynaud's ...... allel-group, controlled trial.
@en
prefLabel
Losartan therapy for Raynaud's ...... allel-group, controlled trial.
@ast
Losartan therapy for Raynaud's ...... allel-group, controlled trial.
@en
P2093
P2860
P1476
Losartan therapy for Raynaud's ...... allel-group, controlled trial.
@en
P2093
Dziadzio M
P2860
P304
P356
10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T
P577
1999-12-01T00:00:00Z